Wednesday, April 29
8 am PT, 11 am ET, 17:00 CET

Speakers:
Aaron K. Sato, Ph.D., CSO, Biopharma, Twist Biopharma, a division of Twist Bioscience
Daniel H. Bedinger, Ph.D., Application Science Team Lead, Carterra

When sorting through a heap of antibody candidates from a library, antibody affinity and binning data are critical for sorting through potential candidates. Twist Biopharma, a division of Twist Bioscience, uses its proprietary DNA writing technology to create large diverse oligo pools (upwards of 106) to develop a range of antibody phage display libraries. These libraries are either broadly applicable to any target or focused on a specific class of tough targets, e.g. GPCRs. Screening Twist’s libraries often discovers a large panel of antibodies to each target, which can be further sorted based on affinity and epitope.

Throughput, speed, resolution, and sample consumption are typically key limiting- factors for detailed kinetic characterization early in antibody discovery campaigns. Here, we show that high throughput surface plasmon resonance (SPR) can be used to rapidly generate high quality kinetic data from 384 antibodies in parallel with minimal sample consumption. Additionally, epitope binning assays can be performed on up to 384 antibodies per array, providing unprecedented throughput that allows for early assessment of your library’s epitope coverage with exquisite epitope discrimination, facilitating the identification of clones targeting unique epitopes. The ability to characterize binding kinetics, affinity, and epitope specificity on large antibody panels with minimal sample consumption at early stage research is highly advantageous in drug discovery because it helps to accelerate library-to-lead triage.

In this webinar, Twist Biopharma will show how the Carterra fits into their workflow to get an early read on affinity and epitope binning. Utilizing this data, they will show how they can winnow their lead candidates down to a smaller number of top candidates to pursue further.

Register Here